Companies /Healthcare

Astrazeneca plc

NASDAQ: AZN Drug Manufacturers - General
$170.08
▼ $1.98 (−1.15%) today
Markets closed · 8:38pm ET

24/7 Wall St. View

AZN at a Glance

Valuation
Market cap
$266.8B
P/E ratio
25.7
Dividend yield
1.88%
Profitability
Revenue (TTM)
$61.4B
Profit margin
17.0%
EPS (TTM)
$6.69
Price
52-week range
$152 – $209
24/7 target
$214.86
Street target
$206.66
Earnings
Next report
Oct 30, 2026

Headquartered in 1 Francis Crick Avenue, Cambridge Fiscal year ends December NASDAQ: AZN astrazeneca.com

About AstraZeneca

AstraZeneca PLC is a global biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription medicines across four main therapy areas: Oncology, Cardiovascular/Renal/Metabolism (CVRM), Respiratory & Immunology (R&I), and Rare Disease, with additional operations in Infectious Disease (Vaccines & Immune Therapies). The company's portfolio includes blockbuster oncology drugs such as Tagrisso (EGFR-mutant lung cancer), Imfinzi (immuno-oncology across lung, liver, bladder, and GI cancers), Lynparza (PARP inhibitor for breast and prostate cancers), Enhertu (HER2-targeted antibody-drug conjugate, partnered with Daiichi Sankyo), and Calquence (BTK inhibitor for blood cancers). In CVRM, Farxiga is a major SGLT2 inhibitor for diabetes, heart failure, and chronic kidney disease, though now facing generic competition. The Rare Disease unit, built on the Alexion acquisition, markets Ultomiris and Soliris for complement-mediated diseases and Strensiq for hypophosphatasia. AstraZeneca partners extensively with companies including Daiichi Sankyo (Enhertu, Datroway), Amgen (Tezspire), Sanofi (Beyfortus), and Merck (Lynparza). The company operates globally with significant revenue contributions from the United States (43%), Europe (22%), and Emerging Markets including China (27%). AstraZeneca is pursuing a target of $80 billion in Total Revenue by 2030, driven by new product launches, indication expansions, and a deep late-stage pipeline with more than 20 high-value readouts expected over the next 18 months. Updated

Latest Activity

Mad Money w/ Jim Cramer 10/27/26

  • Cramer rejects the AI all-clear despite Broadcom arranging $63 billion in financing for Anthropic compute
  • Meta's $25 billion equity raise was five times oversubscribed, but the $60 billion at-the-market program worries him
  • CoreWeave bonds reaching a 15% yield flagged as the sector's unresolved weak spot
  • Caller questions on Micron volatility and Revolution Medicines' pancreatic cancer drug

The bull case for data centers today rested on financing rather than profits, and Cramer wants to hear a customer say the chips are minting money before calling it clear. He expects Meta's at-the-market selling to weigh on the stock as supply hits at the wrong moments, with borrowing costs into a Fed decision the swing factor for everything levered to the buildout.

A 53% cut in death risk versus chemotherapy is the kind of late-stage result that resets an oncology franchise, and it lands after a stretch of pipeline setbacks weighed on the shares. Watch for the full trial data and filing timeline.

BREAKING: AstraZeneca reports major breakthrough in stomach cancer treatment, with its experimental drug reducing the risk of death by 53% compared with chemotherapy in a late-stage trial.
  • Replies24
  • Reposts31
  • Likes237
Biggest movers · On the open
  • INTUIntuit$326.18+5.1%
  • MRSHMarsh$187.37+5.0%
  • AZNAstraZeneca$169.22+4.4%
  • WMTWalmart$121.3+4.4%
  • EXPEExpedia$286.79+4.4%
  • AAOIApplied Optoelectronics$77.49-10.1%
  • CIFRCipher Digital$9.02-9.3%
  • IRENIren$27.76-9.2%
  • DELLDell Technologies$461.71-9.1%
  • SNDKSanDisk$1,277.91-8.9%

The downside is doing the damage at Wednesday's open: Applied Optoelectronics is off 10.13%, with Dell and SanDisk each shedding roughly 9%. The best gainer, Intuit at 5.07%, does not come close to matching it.

AZN Coverage

Frequently Asked Questions

What does AstraZeneca do?

AstraZeneca PLC is a global biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription medicines across four main therapy areas: Oncology, Cardiovascular/Renal/Metabolism (CVRM), Respiratory & Immunology (R&I), and Rare Disease, with additional operations in…

What is the AZN stock price target?

24/7 Wall St.'s 12-month price target for AZN is $214.86, rated Buy. The Wall Street consensus target is $206.66. AZN price prediction →